Evidence map›Paper›PMID 28195946›Full record

ReviewJournal of cardiovascular pharmacology2017

G Protein Coupled Receptor-mediated Transactivation of Extracellular Proteases.

Allison E Schafer, Burns C Blaxall

Abstract readReview
In one paragraph

Review in Journal of cardiovascular pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. ELTD1-An Emerging Silent Actor in Cancer Drama Play.International journal of molecular sciences · 2021
    Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Allison E SchaferThe Heart Institute, Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Burns C Blaxall
Cincinnati Children's Hospital Medical Center · US

Funding

WNT/^-catenin Signaling and Cardiac Fibrosis P01HL069779 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI OSINSKA, HANNA · 2002 to 2017
$27.0M
Intraosseous delivery of lentiviral vectors for hemophilia A gene therapyR01HL134321 · NHLBI · SEATTLE CHILDREN'S HOSPITAL · PI Carol H Miao · 2016 to 2026
$6.2M
Understanding Cardiovascular Disease MechanismsT32HL125204 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Evangelia G Kranias, Jeffery D Molkentin · 2015 to 2026
$3.4M
Targeting pathologic G-protein signaling in cardiac and kidney fibrosisR01HL133695 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI DEVARAJAN, PRASAD, YUTZEY, KATHERINE E · 2016 to 2019
$1.9M
Targeting fibronectin in cardiac remodeling and fibrosisR01HL134312 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI BLAXALL, BURNS C · 2016 to 2018
$1.2M
Targeting Gbg-GRK2 signaling in fibrotic remodelingR01HL132551 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI BLAXALL, BURNS C · 2016 to 2018
$1.2M
Small molecule targeting of MLK3 for heart failureR01HL129772 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI BLAXALL, BURNS C · 2016 to 2018
$1.2M
NHLBI NIH HHS P01 HL069779NHLBI NIH HHS R01 HL129772NHLBI NIH HHS R01 HL132551NHLBI NIH HHS R01 HL133695NHLBI NIH HHS R01 HL134312NHLBI NIH HHS R01 HL134321NHLBI NIH HHS T32 HL125204
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) comprise the largest family of receptors in humans. Traditional activation of GPCRs involves binding of a ligand to the receptor, activation of heterotrimeric G proteins and induction of subsequent signaling molecules. It is now known that GPCR signaling occurs through G protein-independent pathways including signaling through β-arrestin and transactivation of other receptor types. Generally, transactivation occurs when activation of one receptor leads to the activation of another receptor(s). GPCR-mediated transactivation is an essential component of GPCR signaling, as activation of other receptor types, such as receptor tyrosine kinases, allows GPCRs to expand their signal transduction and affect various cellular responses. Several mechanisms have been identified for receptor transactivation downstream of GPCRs, one of which involves activation of extracellular proteases, such as a disintegrin and metalloprotease, and matrix metalloproteases . These proteases cleave and release ligands that are then able to activate their respective receptors. A disintegrin and metalloprotease, and matrix metalloproteases can be activated via various mechanisms downstream of GPCR activation, including activation via second messenger, direct phosphorylation, or direct G protein interaction. Additional understanding of the mechanisms involved in GPCR-mediated protease activation and subsequent receptor transactivation could lead to identification of new therapeutic targets.

Indexed as

AnimalsExtracellular FluidHumansMatrix MetalloproteinasesPeptide HydrolasesReceptors, G-Protein-CoupledSignal TransductionTranscriptional ActivationMatrix MetalloproteinasesPeptide HydrolasesReceptors, G-Protein-Coupled

Identifiers

PMID28195946
PMCPMC5498247
OpenAlexW2588655047

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.